

## Research Article

# Applicability of 14 Formulas for Estimating Glomerular Filtration Rate in the Evaluation of Renal Function before and after Nephron-Sparing Surgery in Patients with Renal Tumors

Qiuyan Li <sup>1</sup>, ZeSong Yang,<sup>1</sup> Shiwen Zheng <sup>2</sup>, Yangbiao Wu,<sup>1</sup> Wanghai Cai,<sup>1</sup> Minxiong Hu,<sup>1</sup> Qingguo Zhu,<sup>1</sup> and Liefu Ye <sup>1</sup>

<sup>1</sup>Shengli Clinical Medical College of Fujian Medical University and Department of Urology, Fujian Provincial Hospital, Fuzhou 350001, China

<sup>2</sup>Medical College, Anhui University of Science and Technology, Huainan 232000, China

Correspondence should be addressed to Liefu Ye; [yeliefu@fjmu.edu.cn](mailto:yeliefu@fjmu.edu.cn)

Received 2 April 2022; Revised 18 April 2022; Accepted 21 April 2022; Published 9 May 2022

Academic Editor: Mohammad Farukh Hashmi

Copyright © 2022 Qiuyan Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

To compare the applicability of 14 equations of estimating glomerular filtration rate (eGFR) before and after nephron-sparing surgery (NSS) for renal function assessment of patients with renal tumors. Preoperative and postoperative GFR is measured by emission computed tomography (ECT) with <sup>99m</sup>Tc-DTPA as an imaging agent as reference GFR (rGFR) to compare with all formulas. Spearman correlation analysis and Bland-Altman agreement analysis were used to evaluate the correlation between rGFR and eGFR1 to 14 before and after surgery. A total of 50 cases including 22 males and 28 females were included. The results of preoperative eGFR1-14 correlated with rGFR ( $P < 0.05$ ). The calculation results of all estimation formulas have a significant correlation with preoperative GFR. Preoperative MDRD-I, CKD-EPI<sub>SCysC</sub>, and FAS<sub>Scr-SCysC</sub> have good consistency. The CG formula has the highest precision and FAS<sub>Scr-SCysC</sub> has the highest accuracy. A total of 30 patients followed up after surgery, and postoperative rGFR correlated with CG, CKD-EPI, FAS, and BIS formulas ( $P < 0.05$ ). But postoperative rGFR has no significant correlation with MDRD and Schwartz ( $P > 0.05$ ). Postoperative CKD-EPI<sub>Scr-SCysC</sub> has best consistency, and FAS<sub>Scr-SCysC</sub> has the highest accuracy and precision. Our data suggest that eGFR equations evaluated by both serum creatinine (Scr) and cystatin C (SCysC) is not necessarily better than those evaluated by one of them alone. Among all enrolled equations, FAS<sub>Scr-SCysC</sub> is the best one to evaluate postoperative GFR in patients with renal tumors.

## 1. Introduction

GFR refers to the number of milliliters of plasma that the kidneys completely filter and clear a certain metabolite in plasma within a unit time [1]. It is an important indicator for effectively evaluating the renal function of patients [2]. Methods based on the clearance of exogenous markers, like inulin, <sup>51</sup>Cr-EDTA, and iohexol, are the gold standard for glomerular filtration rate (GFR) measurement, but are cumbersome and infrequently used in clinical settings [3]. At present, the clinically accurate determination of GFR mainly relies on ECT, with proven ease of operation and good repeatability [4]. In clinical work, relying on the biochemical results of renal function in the laboratory, such

as Scr, blood urea nitrogen (BUN), and SCysC, calculating GFR through formulas is more convenient, easy, economical, and less harmful to patients [5].

Since the Cockcroft-Gault (CG) formula was widely used in clinical practice in 1976 [6], eGFR formulas based on Scr and SCysC have been developed endlessly. The National Kidney Foundation (NKF) guidelines recommend the use of the CG formula, MDRD (modification of diet in renal disease) formula, and CKD-EPI (chronic kidney disease epidemiology collaboration) formula [7], but the results of the current studies have not confirmed that the above recommended formula is the optimal one. Studies have shown that Scr-based CKD-EPI has better applicability than MDRD [8, 9]. The research results of Liu et al. on adult CKD patients

in China show that the CG formula has better applicability [10]. At present, the commonly used formulas in clinical practice are FAS (full age spectrum), MDRD-I, MDRD -II, MDRD-China (MDRD-C), CKD-EPI (Scr), BIS-1 formula, Schwartz's formula, and so on. Estimated glomerular filtration rate (eGFR) is prone to bias in specific situations or special populations [11]. So far, there are few studies in China that systematically evaluate the difference in eGFR calculation results of patients with kidney tumors before and after nephron-sparing surgery. We used all 14 estimating formulas to calculate the GFR of renal tumor patients undergoing nephron-sparing surgery to verify the applicability of various formulas to renal tumor patients in my country.

## 2. Materials and Methods

**2.1. Sources of Data and Measurements.** A total of 50 patients with renal tumor who underwent NSS in Fujian Provincial Hospital from July 2020 to July 2021 were enrolled. All patients had no renal puncture, interventional surgery, radiotherapy, or chemotherapy, or other antitumor-related treatments before surgery. No history of CKD disease, renal trauma, and surgery. Clinical data include gender, age, height, weight, preoperative creatinine, urea, nitrogen, albumin (Alb), cystatin C, rGFR measured by ECT, and pathological diagnosis, as given in Table 1.

The patient's serum creatinine concentration was measured with the alkaline picric acid method using the Beckman CX3 analyzer. Serum cystatin C was measured on the Beckman UniCel Dx C800 biochemical analyzer with the latex enhanced immunoturbidimetric method.

<sup>99m</sup>Tc-DTPA imaging determination rGFR: before the examination, the patient drinks 300–500 ml of water, empties the bladder, and takes the supine position. The probe is placed on the back waist, and the field of view includes both the kidneys and bladder. The imaging agent is injected into the vein of one side of the elbow in the form of a "bullet," and two sets of images of blood perfusion and renal function are dynamically collected in two phases. The acquisition field includes the kidneys, ureters, and bladder. The first phase is 1 s/frame, and 60 frames are collected. The second phase is 20 s/frame, and the collection is 29 minutes. After the collection is completed, the empty syringe is collected again and counted for 6 s. Calculate the dose of drug injected into the body according to the count value of the syringe before and after. Use the ROI technology to outline the outline and background area of the kidneys. Then, use the supporting software to process the image and generate the kidney map to obtain the GFR of the kidneys.

**2.2. Statistical Analysis.** The measured height, weight, Scr, BUN, Alb, and SCysC values were, respectively, substituted into the 14 estimation equations included in this study, and eGFR1–14 were calculated, as given in Table 2. Using SPSS 16.0 and MedCalc 15.2.2 statistical software, perform analysis. Spearman correlation analysis and Bland–Altman agreement analysis were used to evaluate the correlation between rGFR and eGFR1–14 before and after surgery.

Accuracy means the degree to which the measured value of the formula is consistent with rGFR, indicating the correctness of the calculation result. The greater the number of close agreement between the eGFR results and rGFR values of multiple patients calculated by each formula, the higher the precision of the results, showing the repeatability and stability of the formula.

## 3. Results

A total of 50 cases including 22 males and 28 females, aged 17–80 years old, with an average of  $53.8 \pm 10.2$  years old (male),  $50 \pm 10.5$  years old (female). The average preoperative rGFR of 50 patients was  $90.04 \pm 15.42$  (male) and  $91.71 \pm 19.67$  (female). Only 3 patients had rGFR less than  $60 \text{ ml/min/1.73 m}^{-2}$  and no patients had rGFR less than  $30 \text{ ml/min/1.73 m}^{-2}$ . Of the 30 patients followed up after surgery, there were 12 males with an average of  $56.1 \pm 13.1$  years old and 18 females with  $48.8 \pm 11.2$  years old. The average time from surgery to reexamination of rGFR for 30 patients was 262 days. The average postoperative rGFR of 30 patients was  $93.94 \pm 20.26$  (male) and  $93.49 \pm 22.62$  (female).

**3.1. Correlation Analysis of Preoperative eGFR and rGFR.** rGFR is correlated with all preoperative GFR calculated by each formula ( $P < 0.05$ ), among which eGFR1 (CG formula), eGFR6 (CKD-EPI<sub>Scr</sub>), eGFR7 (CKD-EPI<sub>SCysC</sub>), eGFR8 (CKD-EPI<sub>Scr-SCysC</sub>), eGFR9 (Schwartz<sub>Scr-SCysC</sub>), eGFR10 (FAS<sub>Scr</sub>), eGFR11 (2017 FAS<sub>SCysC</sub>), eGFR12 (FAS<sub>Scr-SCysC</sub>), eGFR13 (BIS-1<sub>Scr</sub>), and eGFR14 (BIS-2<sub>Scr-SCysC</sub>) have a significant correlation ( $P \leq 0.001$ ), as given in Table 3.

**3.2. Consistency Analysis of Preoperative eGFR and rGFR.** The mean line of eGFR2 (MDRD-I) is closest to 0, indicating that its calculation result is closest to rGFR, as shown in Figure 1.

The closest moving average value to 0 is  $-0.13$  (B). Only one calculated eGFR value was outside the 95% CI (B, G, L). The absolute minimum value of the intercept width is  $-0.2096$  (A). The absolute value of the slope is the smallest, which is  $-0.0144$  (L). The absolute value of the slope is the largest at  $-0.7026$  (M).

Followed by eGFR10 (FAS<sub>Scr</sub>), the average line is only 1.8. The eGFR2 (MDRD-I), eGFR7 (CKD-EPI<sub>SCysC</sub>), and eGFR12 (FAS<sub>Scr-SCysC</sub>) have good consistency, and only one patient's GFR is outside the 95% confidence interval (95% CI).

Among the 14 formulas, the absolute value of the intercept width of eGFR1 (CG formula) is the smallest, which is  $-0.2096$ , indicating that eGFR1 (CG formula) has highest accuracy than other formulas. Followed by eGFR12 (FAS<sub>Scr-SCysC</sub>) and eGFR7 (CKD-EPI<sub>SCysC</sub>) are  $-5.0456$  and  $-5.4934$  respectively. The minimum absolute value of the slope of eGFR12 (FAS<sub>Scr-SCysC</sub>) is  $-0.0144$ , indicating the highest accuracy. Followed by eGFR1 (CG formula) and eGFR7 (CKD-EPI<sub>SCysC</sub>), they are  $-0.0516$  and  $-0.0592$ , respectively. Among the CKD-EPI related formulas (eGFR6, eGFR7, and eGFR8), the cystatin C-based formula has the highest

TABLE 1: Basic characteristics of the 50 patients.

Characteristic ( <i>n</i> = 50)	Male	Female
<i>N</i>	22	28
Age (years)	17–80	29–73
Average age (years)	53.8 ± 10.2	50.0 ± 10.5
Height (cm)	171.6 ± 6.1	159.0 ± 4.1
Weight (kg)	70.4 ± 9.2	57.4 ± 6.6
Plasma creatinine (mg/dl)	0.94 ± 0.086	0.75 ± 0.089
Plasma urea nitrogen (mg/dl)	98.9 ± 21.5	91.1 ± 18.5
Plasma albumin (g/dl)	440.0 ± 20.0	433.2 ± 26.3
rGFR (ml/min/1.73 m <sup>-2</sup> )	90.04 ± 15.42	91.72 ± 19.67
Tumor size (cm)	3.3 (1.3–10.5)	4.1 (0.8–8.0)
rGFR category		
rGFR ≥ 90	10	14
60 ≤ rGFR < 90	12	11
rGFR < 60	—	3
Pathologic type		
Angiomyolipoma (AML)	3	11
chrCC	2	—
ccRCC	16	13
Mucinous tubular and spindle cell carcinoma	—	1
ESC RCC	1	—
RNET	—	1
Others	—	2

rGFR, reference glomerular filtration rate; tumor size, the maximum diameter of the tumor; AML, angiomyolipoma; chrCC, chromophobe renal cell carcinoma; ccRCC, clear cell renal cell carcinoma; ESC RCC, eosinophilic solid and cystic renal cell carcinoma; RNET, renal neuroendocrine tumor.

TABLE 2: 14 formulas for calculating the glomerular filtration rate.

eGFR1	CG formula [6]: $(0.85 \text{ if female}) \times (140 - \text{age}) \times \text{bodyweight} / (72 \times \text{Scr})$
eGFR2	MDRD (simplified) I [12]: $186 \times \text{Scr}^{-1.154} \times \text{age}^{-0.203} \times (0.742 \text{ if female})$
eGFR3	MDRD (simplified) II [13]: $175 \times \text{Scr}^{-1.154} \times \text{age}^{-0.203} \times (0.742 \text{ if female})$
eGFR4	MDRD-C (for Chinese) [14]: $186 \times \text{Scr}^{-1.154} \times \text{age}^{-0.203} \times (0.742 \text{ if female}) \times (1.233 \text{ if Chinese})$
eGFR5	MDRD formula [15]: $170 \times \text{Scr}^{-0.199} \times \text{age}^{-0.176} \times \text{BUN}^{-0.17} \times \text{Alb}^{0.138} \times (0.762 \text{ if female})$ CKD-EPI <sub>Scr</sub> [16]: $a \times (\text{Scr}/b)^c \times 0.399^{\text{age}}$ $a = 144 \text{ (if female), } a = 141 \text{ (if male)}$ $b = 0.7 \text{ (if female), } b = 0.9 \text{ (if male)}$
eGFR6	$c = -0.329 \text{ when } \text{Scr} \leq 0.7 \text{ mg/dL (if female); } c = -1.209 \text{ when } \text{Scr} > 0.7 \text{ mg/dL (if female);}$ $c = -0.441 \text{ when } \text{Scr} \leq 0.9 \text{ mg/dL (if male); } c = -1.209 \text{ when } \text{Scr} > 0.9 \text{ mg/dL (if male)}$
eGFR7	CKD-EPI <sub>SCysC</sub> [17]: $133 \times (\text{SCysC}/0.8)^a \times (0.996)^{\text{age}} \times (0.932 \text{ if female});$ $a = -0.499 \text{ when } \text{SCysC} \leq 0.8 \text{ mg/l; } a = -1.328 \text{ when } \text{SCysC} > 0.8 \text{ mg/L}$ CKD-EPI <sub>Scr-SCysC</sub> [17]: $a \times (\text{Scr}/b)^c \times (\text{SCysC}/0.8)^d \times (0.995)^{\text{age}}$ $a = 130 \text{ (if female), } a = 135 \text{ (if male)}$ $b = 0.7 \text{ (if female), } b = 0.9 \text{ (if male)}$
eGFR8	$c = -0.248 \text{ when } \text{Scr} \leq 0.7 \text{ mg/dL (if female); } c = -0.601 \text{ when } \text{Scr} > 0.7 \text{ mg/dL (if female);}$ $c = -0.207 \text{ when } \text{Scr} \leq 0.9 \text{ mg/dL (if male); } c = -0.601 \text{ when } \text{Scr} > 0.9 \text{ mg/dL (if male)}$ $d = -0.375 \text{ when } \text{SCysC} \leq 0.8 \text{ mg/L; } d = -0.711 \text{ when } \text{SCysC} > 0.8 \text{ mg/L}$
eGFR9	Schwartz <sub>Scr-SCysC</sub> [18]: $39.8 \times (\text{height}/\text{Scr})^{0.456} \times (1.8/\text{SCysC})^{0.418} \times (30/\text{BUN})^{0.079}$ $\times (1.076 \text{ if male}) \times (\text{height}/1.4)^{0.179}$
eGFR10	FAS <sub>Scr</sub> [19]: $107.3 / (\text{Scr}/\text{QScr})$ when $2 \leq \text{age} \leq 40$ $0.988 (\text{age}^{-40}) \times 107.3 / (\text{Scr}/\text{QScr})$ when $\text{age} > 40$ $\text{QScr} = 0.7 \text{ mg/dL (if female); } \text{QScr} = 0.9 \text{ mg/dL (if male)}$
eGFR11	FAS <sub>SCysC</sub> [20]: $107.3 / (\text{SCysC}/\text{Q}_{\text{SCysC}})$ when $2 \leq \text{age} \leq 40$ $0.988 (\text{age}^{-40}) \times 107.3 / (\text{SCysC}/\text{Q}_{\text{SCysC}})$ when $\text{age} > 40$ $\text{Q}_{\text{SCysC}} = 0.82 \text{ when } \text{age} < 70; \text{Q}_{\text{SCysC}} = 0.95 \text{ when } \text{age} \geq 70$
eGFR12	FAS <sub>Scr-SCysC</sub> [20]: $0.988 (\text{age}^{-40}) \times 107.3 / [\alpha \times \text{Scr}/\text{Q}_{\text{Scr}} + (1 - \alpha) \times \text{SCysC}/\text{Q}_{\text{SCysC}}]$ when $\text{age} > 40$ $\text{Q}_{\text{SCysC}} = 0.82 \text{ when } \text{age} < 70; \text{Q}_{\text{SCysC}} = 0.95 \text{ when } \text{age} \geq 70 \alpha = 0.5$
eGFR13	BIS - 1 <sub>Scr</sub> [21]: $3736 \times \text{Scr}^{-0.87} \times \text{age}^{-0.95} \times (0.82 \text{ if female})$
eGFR14	BIS - 2 <sub>Scr-SCysC</sub> [21]: $767 \times \text{SCysC}^{-0.61} \times \text{Scr}^{-0.40} \times \text{age}^{-0.57} \times (0.87 \text{ if female})$

TABLE 3: Spearman correlation analysis of 14 evaluation formulas for preoperative GFR.

Formulas	eGFR (ml/min/1.73 m <sup>-2</sup> )	Spearman's correlation	
		<i>r</i>	<i>P</i>
rGFR	90.98 ± 22.90	—	—
eGFR1	86.61 ± 22.03	0.564	0.000
eGFR2	91.11 ± 15.42	0.413	0.003
eGFR3	85.72 ± 14.51	0.413	0.003
eGFR4	112.34 ± 19.01	0.413	0.003
eGFR5	97.64 ± 15.97	0.421	0.002
eGFR6	92.96 ± 15.49	0.524	0.000
eGFR7	102.19 ± 24.00	0.541	0.000
eGFR8	99.05 ± 10.05	0.561	0.000
eGFR9	102.54 ± 15.60	0.455	0.001
eGFR10	89.18 ± 17.41	0.547	0.000
eGFR11	104.05 ± 34.59	0.555	0.000
eGFR12	94.69 ± 22.64	0.590	0.000
eGFR13	102.83 ± 38.33	0.548	0.000
eGFR14	101.68 ± 31.10	0.586	0.000

Comparison of the correlation between eGFR and rGFR of each formula,  $P < 0.05$ .

consistency than the equation based on creatinine and the combination formula. The FAS<sub>Scr-SCysC</sub> formula has the highest consistency than those based on creatinine or cystatin C alone.

### 3.3. Correlation Analysis of Postoperative eGFR and rGFR.

The postoperative GFR of 30 patients measured in 14 formulas was analyzed by Spearman correlation with rGFR. The results are given in Table 4. The rGFR is correlated with eGFR1 (CG formula), eGFR6 (CKD-EPI<sub>Scr</sub>), eGFR7 (CKD-EPI<sub>SCysC</sub>), eGFR8 (CKD-EPI<sub>Scr-SCysC</sub>), eGFR10 (FAS<sub>Scr</sub>), eGFR11 (2017 FAS<sub>SCysC</sub>), eGFR12 (FAS<sub>Scr-SCysC</sub>), eGFR13 (BIS-1<sub>Scr</sub>), and eGFR14 (BIS-2<sub>Scr-SCysC</sub>) ( $P < 0.05$ ). But rGFR has no significant correlation with eGFR2 (MDRD-I), eGFR3 (MDRD-II), eGFR4 (MDRD-C), eGFR5 (MDRD), and eGFR9 (Schwartz<sub>Scr-SCysC</sub>) ( $P > 0.05$ ).

### 3.4. Consistency Analysis of Postoperative eGFR and rGFR.

Among eGFR1–14, the absolute value of the arithmetic mean of eGFR8 (CKD-EPI<sub>Scr-SCysC</sub>) is closest to 0. Then, there are eGFR14 (BIS-2<sub>Scr-SCysC</sub>), eGFR5 (MDRD), and eGFR11 (2017 FAS<sub>SCysC</sub>), which have good consistency for arithmetic mean less than 2. The arithmetic mean of eGFR4 (MDRD-C) is 17.1, which is the largest value among the 14 formulas.

All calculated GFR values of eGFR8 (CKD-EPI<sub>Scr-SCysC</sub>) are within 95% CI means it has better consistency. Except for eGFR4 (MDRD-C) and eGFR10 (FAS<sub>Scr</sub>), which have two GFR values outside the 95% CI, there is only one other formula. Among the 14 formulas, the absolute value of the slope and intercept of eGFR12 (FAS<sub>Scr-SCysC</sub>) is the smallest, indicating that its accuracy and precision are the highest. The accuracy of eGFR4 (MDRD-C), eGFR7 (CKD-EPI<sub>SCysC</sub>), eGFR10 (FAS<sub>Scr</sub>), and eGFR1 (CG formula) is higher, for the absolute value of their slopes are all less than 0.1. The

absolute values of the intercepts of eGFR10 (FAS<sub>Scr</sub>) and eGFR7 (CKD-EPI<sub>SCysC</sub>) are smaller than those of other formulas, indicating that the accuracy of these two formulas is higher than others, as given in Table 4.

## 4. Discussion

In recent years, with the development of early screening for malignant tumors and the improvement of people's health awareness, the early diagnosis rate of renal tumors has increased significantly. The correct assessment of renal function is of great importance to decide surgical strategy. GFR is a direct indicator for evaluating renal function. GFR measurement of the patients with renal tumor before and after nephron-sparing surgery may be important in treatment strategy decision and prognosis evaluation. The removal rate of inulin is an ideal method for measuring GFR, but procurement of inulin and the cumbersome procedure pose a challenge for its routine clinical use. Among many GFR estimation formulas, how to choose an appropriate formula is a puzzled problem faced by clinicians. In recent years, most of the eGFR evaluation equations have been verified by patients with chronic kidney disease, and the eGFR formula is rarely used in the evaluation of renal function in patients with renal tumors. We use the 99mTc-DTPA renal function imaging method to measure GFR as the reference standard (rGFR) [22] to assess the applicability of 14 commonly used formulas in patients with renal tumors.

The results of the study showed that there was a significant correlation between the GFR calculated by the 14 estimation formulas and rGFR before the surgery. Studies have shown that the combined formula of serum creatinine and cystatin C is better than using one of them alone [23, 24]. Among the 14 formulas included in this study, the calculation results of the three formulas including MDRD-I, CG formula, CKD-EPI<sub>SCysC</sub>, and FAS<sub>Scr-SCysC</sub> are in good agreement with rGFR. Among them, the CG formula has the highest precision, and FAS<sub>Scr-SCysC</sub> has the highest accuracy. Renal tumors can occur in almost all age groups [25]. The FAS formula is suitable for patients of all ages and has good applicability for preoperative renal function assessment [19].

In the results calculated after the operation, 5 formulas had no significant correlation ( $P > 0.05$ ), including MDRD-I, MDRD-II, MDRD-C, MDRD, and Schwartz<sub>Scr-SCysC</sub>. These formulas have limitations for the evaluation of renal function in patients with renal tumors after surgery. The Schwartz formula is mainly used to evaluate the renal function of children with CKD [18]. The youngest age of the patients in this study is 17 years old. Therefore, it is verified that the Schwartz formula is not highly applicable to patients over 14 years of age. In the evaluation of renal function in adult patients with renal tumors after surgery, this method is not recommended.

In 1999, the US MDRD research team found that age, gender, and race were independent variables of GFR and derived the original MDRD formula [15]. In 2000 and 2007, MDRD-I and MDRD-II were obtained by improving the formula [12, 13]. In 2006, the Chinese eGFR project




FIGURE 1: Bland–Altman plot of preoperative eGFR and rGFR in 50 patients.

coworker group researched and imitated the development process of the MDRD formula to arrive at the improved c-MDRD formula [14]. In our study, the calculation results of the four MDRD correlation formulas have no significant

correlation with rGFR, indicating that they are not suitable for eGFR calculations for postoperative patients. The National Kidney Foundation (NKF) and the American Society of Nephrology (ASN) established a joint working group in

TABLE 4: Spearman correlation analysis and Bland–Altman agreement analysis of 14 eGFR and rGFR after surgery.

Formula	eGFR	Spearman's correlation		Arithmetic mean	Slope	Intercept	95% CI ( <i>n</i> (%))
		R	P				
rGFR	93.67 ± 22.08	—	—	—	—	—	—
eGFR1	87.92 ± 23.51	0.499	0.005	−5.7262	0.08306	−13.2684	29/30
eGFR2	89.97 ± 18.30	0.305	*0.101	−3.7002	−0.2787	21.8890	29/30
eGFR3	84.65 ± 17.22	0.305	*0.101	−9.0210	−0.3672	23.7211	29/30
eGFR4	110.93 ± 22.57	0.305	*0.101	17.2630	0.03263	13.9253	28/30
eGFR5	94.77 ± 19.47	0.324	*0.081	1.0985	−0.1824	18.2889	29/30
eGFR6	91.49 ± 17.38	0.421	0.021	−2.1787	−0.3217	27.6003	29/30
eGFR7	95.27 ± 23.23	0.444	0.014	1.6039	0.06294	−4.3426	29/30
eGFR8	94.02 ± 19.33	0.471	0.009	0.3488	−0.1644	15.7741	30/30
eGFR9	97.34 ± 14.49	0.284	*0.128	3.6656	−0.5510	56.2854	29/30
eGFR10	88.86 ± 21.03	0.480	0.007	−4.8075	−0.06502	1.1269	28/30
eGFR11	95.11 ± 27.50	0.511	0.004	1.4373	0.2681	−23.8695	29/30
eGFR12	90.69 ± 21.65	0.537	0.002	−2.9858	−0.02436	−0.7408	29/30
eGFR13	100.77 ± 34.90	0.581	0.001	7.0974	0.5963	−50.8760	29/30
eGFR14	94.74 ± 24.52	0.582	0.001	1.0664	0.1288	−11.0627	29/30

\* $P > 0.05$ , no significant correlation ; 95% CI, numbers within 95% CI.

2020 to evaluate the eGFR estimation formula [26]. On November 4, 2021, NEJM officially published the results of two research teams on eGFR estimation of race coefficient. The results of these two studies show that the eGFR estimation formula based on serum cystatin C is more accurate than the estimation formula based on serum creatinine [27]. So, they recommended the following: the race coefficient has limited influence on the eGFR calculation, and the race coefficient can be removed; each clinical laboratory should try its best to detect serum cystatin C; and further research to find better markers for eGFR estimation [26, 27]. The population included in the MDRD study is mainly concentrated in patients aged 18–70 [15]. Past studies have shown that when patients have low GFR, the MDRD simplified formula is less accurate and tends to underestimate renal function [28]. The renal function of patients after renal surgery has declined to a certain extent. Therefore, the MDRD formula is not suitable for postoperative renal function assessment. But, we should not ignore the possibility of errors caused by the reduction in sample size.

In 2016, Pottel et al. proposed an eGFR equation based on  $Scr/Q_{Scr}$  that is applicable to all-year-olds (full age spectrum, FAS), where  $Q_{Scr}$  is the median number of Scr for healthy people of a specific age and gender [19]. In 2017, the research group used cystatin C instead of Scr and proposed the FAS<sub>SCysC</sub> formula and the FAS<sub>Scr-SCysC</sub> formula [20]. Studies on the applicability of the FAS formula in the Chinese population have confirmed that FAS<sub>Scr-SCysC</sub> has higher applicability in China [29]. In this study, GFR calculated by FAS<sub>Scr-SCysC</sub> formula after surgery has the highest accuracy and precision. Patients after surgery are recommended to use this equation for renal function assessment.

In 2009, the United States Chronic Kidney Disease Epidemiology Cooperative Group proposed the CKD-EPI<sub>Scr</sub> formula using Scr, age, gender, and race as calculation variables [16]. In 2012, the CKD-EPI research group proposed the CKD-EPI<sub>SCysC</sub> formula and the CKD-EPI<sub>Scr-SCysC</sub> formula based on standardized Scr and SCysC [17]. In the comparison and

verification of the three CKD-EPI formulas, it is found that the combined formula has no significant difference in calculation deviation compared with the two separate formulas, but the precision and diagnostic accuracy are higher [30]. Our results show that the calculation results of the CKD-EPI<sub>Scr-SCysC</sub> formula are highly consistent, and the postoperative GFR calculated by CKD-EPI<sub>SCysC</sub> is more accurate than the other two formulas. These reflect the advantage of cystatin C in early recognition of renal function damage. CKD-EPI formula is mainly derived and established based on CKD patients as the baseline data. The applicability of the formula is different because of the significant differences in renal pathology between patients with renal cancer and CKD.

The BIS-1-2 formula is based on a study of elderly CKD white patients over 70 years of age [21]. In this study, neither preoperative nor postoperative renal function assessment has good applicability.

## 5. Conclusion

For renal function assessment in patients with renal tumors before surgery, eGFR1–14 are all significantly correlated. Among them, the MDRD-I formula can more accurately estimate the GFR of patients. In similar formulas, there is no accurate conclusion about which is better for creatinine or cystatin. In the CKD-EPI formula, the formula of using cystatin C alone is more consistent. While in the FAS formula, the combination of the two is required to calculate GFR more accurately. After surgery, the MDRD-related formula and Schwartz<sub>Scr-SCysC</sub> are not applicable in the calculation of glomerular filtration rate. Among them, CKD-EPI<sub>Scr-SCysC</sub> has good consistency in the assessment of postoperative GFR in patients with renal cancer. The FAS<sub>Scr-SCysC</sub> formula has the highest accuracy and precision. Both of these are recommended for clinical use. However, in this study, due to the small number of postoperative patients, large-scale and sample size clinical studies can still be carried out in the future to confirm it.

## Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

## Ethical Approval

The study was approved from by the Ethics Committee of Fujian Provincial Hospital. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

## Consent

Informed consent was obtained from all subjects.

## Conflicts of Interest

The authors declare that they have no conflicts of interest.

## Authors' Contributions

Qiuyan Li collected and analyzed data and wrote and edited the manuscript. Zesong Yang collected and analyzed data and edited the manuscript. Shiwen Zheng statistically analyzed data and wrote the manuscript. Wanghai Cai, Minxiong Hu, Yangbiao Wu, and Qingguo Zhu collected data. Liefu Ye designed and implemented the research.

## Acknowledgments

This study was supported by grants from 2021 Provincial Natural Fund of Fujian Province of China (2021J1398 to Liefu Ye).

## References

- [1] J. Hephzibah, N. Shanthly, and R. Oommen, "Comparison of glomerular filtration rate measured by plasma sample technique, Cockcroft Gault method and Gates' method in voluntary kidney donors and renal transplant recipients," *Indian Journal of Nuclear Medicine*, vol. 28, no. 3, pp. 144–151, 2013.
- [2] C. W. Zhang, G. Huang, Q. W. Wang, M. L. Ya, and L. Wang, "Influence of renal function by transplant operation for living-related kidney donors in a short term," *Chinese Medical Journal*, vol. 132, no. 5, pp. 618–621, 2019.
- [3] J. Rhee, J. M. Kwon, S. H. Han et al., "Cockcroft-gault, modification of diet in renal disease, and chronic kidney disease epidemiology collaboration equations for estimating glomerular filtration rates in cancer patients receiving cisplatin-based chemotherapy," *Kidney Research and Clinical Practice*, vol. 36, no. 4, pp. 342–348, 2017.
- [4] J. Ren, Z. Huo, X. Wang, Y. Liu, and G. Yang, "Serial renography for evaluation of the impact of capecitabine therapy on renal function: a case report," *Medicine*, vol. 96, no. 22, e6861 pages, 2017.
- [5] S. Z. Wang and Z. H. Qin, "Anti-inflammatory and immune regulatory actions of naja naja atra venom," *Journal of Toxins*, vol. 10, 2018.
- [6] D. W. Cockcroft and M. H. Gault, "Prediction of creatinine clearance from serum creatinine," *Nephron*, vol. 16, no. 1, pp. 31–41, 1976.
- [7] A. A. Soares, A. B. Prates, L. S. Weinert, F. V. Veronese, A. M. De, and S. P. Silveiro, "Reference values for glomerular filtration rate in healthy Brazilian adults," *BMC Nephrology*, vol. 14, no. 1, p. 54, 2013.
- [8] M. Jalalonmuhali, S. Lim, S. M. Md, and K. Ng, "MDRD vs. CKD-EPI in comparison to 51Chromium EDTA: a cross sectional study of Malaysian CKD cohort," *BMC Nephrology*, vol. 18, no. 1, p. 363, 2017.
- [9] L. Tang, X. Y. Ding, L. F. Duan et al., "A regression model to predict augmented renal clearance in critically ill obstetric patients and effects on vancomycin treatment," *Frontiers in Pharmacology*, vol. 12, Article ID 622948, 2021.
- [10] X. Liu, L. Lv, C. Wang et al., "Comparison of prediction equations to estimate glomerular filtration rate in Chinese patients with chronic kidney disease," *Internal Medicine Journal*, vol. 42, no. 5, pp. e59–e67, 2012.
- [11] A. Mogueo, T. J. Echouffo, T. E. Matsha, R. T. Erasmus, and A. P. Kengne, "Validation of two prediction models of undiagnosed chronic kidney disease in mixed-ancestry South Africans," *BMC Nephrology*, vol. 16, no. 1, p. 94, 2015.
- [12] A. Levey, J. Bosch, J. Lewis, S. Reza, N. Rogers, and R. David, "A simplified equation to predict glomerular filtration rate from serum creatinine," *J Am Soc Nephrol*, vol. 11, p. 155A, 2000.
- [13] A. S. Levey, J. Coresh, T. Greene et al., "Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values," *Clinical Chemistry*, vol. 53, no. 4, pp. 766–772, 2007.
- [14] C. E. I. Collaboration, "Modification and evaluation of MDRD estimating equation for Chinese patients with chronic kidney disease," *Chin J Nephrol*, vol. 22, no. 10, pp. 589–595, 2006.
- [15] A. S. Levey, J. P. Bosch, J. B. Lewis, T. Greene, N. Rogers, and D. Roth, "A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation," *Annals of Internal Medicine*, vol. 130, no. 6, pp. 461–470, 1999.
- [16] A. S. Levey, L. A. Stevens, C. H. Schmid et al., "A new equation to estimate glomerular filtration rate," *Annals of Internal Medicine*, vol. 150, no. 9, pp. 604–612, 2009.
- [17] L. A. Inker, C. H. Schmid, H. Tighiouart et al., *New England Journal of Medicine*, vol. 367, no. 1, pp. 20–29, 2012.
- [18] G. . Schwartz, M. F. Schneider, P. S. Maier et al., "Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C," *Kidney International*, vol. 82, no. 4, pp. 445–453, 2012.
- [19] H. Pottel, L. Hoste, L. Dubourg et al., "An estimated glomerular filtration rate equation for the full age spectrum," *Nephrology Dialysis Transplantation*, vol. 31, no. 5, pp. 798–806, 2016.
- [20] H. Pottel, P. Delanaye, E. Schaeffner et al., *Nephrology Dialysis Transplantation*, vol. 32, pp. gfw425–507, 2017.
- [21] E. S. Schaeffner, N. Ebert, P. Delanaye et al., "Two novel equations to estimate kidney function in persons aged 70 Years or older," *Annals of Internal Medicine*, vol. 157, no. 7, pp. 471–481, 2012.
- [22] G. Yildiz, K. Mağden, Y. Abdulkirim, F. Ozcicek, E. Hur, and F. Candan, "Glomerular filtration rate: which method should we measure in daily clinical practice?" *Minerva Medica*, vol. 104, no. 6, pp. 613–623, 2013.

- [23] A. N. Mian and G. J. Schwartz, "Measurement and estimation of glomerular filtration rate in children," *Advances in Chronic Kidney Disease*, vol. 24, no. 6, pp. 348–356, 2017.
- [24] X.-H. Chi, G.-P. Li, Q. S. Wang et al., "CKD-EPI creatinine-cystatin C glomerular filtration rate estimation equation seems more suitable for Chinese patients with chronic kidney disease than other equations," *BMC Nephrology*, vol. 18, no. 1, p. 226, 2017.
- [25] M. W. Ball and C. J. Ricketts, "Complexities in estimating the true risk of hereditary leiomyomatosis and renal cell carcinoma and the development of kidney cancer," *Cancer*, vol. 126, no. 16, pp. 3617–3619, 2020.
- [26] R. M. Gama, A. Clery, K. Griffiths et al., "Estimated glomerular filtration rate equations in people of self-reported black ethnicity in the United Kingdom: inappropriate adjustment for ethnicity may lead to reduced access to care," *PLoS One*, vol. 16, no. 8, Article ID e0255869, 2021.
- [27] C. Y. Hsu, W. Yang, R. V. Parikh et al., "Race, genetic ancestry, and estimating kidney function in CKD," *New England Journal of Medicine*, vol. 385, no. 19, pp. 1750–1760, 2021.
- [28] T. H. Jafar, C. H. Schmid, and A. S. Levey, "Serum creatinine as marker of kidney function in south asians: a study of reduced GFR in adults in Pakistan," *Journal of the American Society of Nephrology*, vol. 16, no. 5, pp. 1413–1419, 2005.
- [29] Z. Yong, F. Li, X. Pei et al., "A comparison between 2017 FAS and 2012 CKD-EPI equations: a multi-center validation study in Chinese adult population," *International Urology and Nephrology*, vol. 51, no. 1, pp. 139–146, 2019.
- [30] T. W. Ferguson, P. Komenda, and N. Tangri, "Cystatin C as a biomarker for estimating glomerular filtration rate," *Current Opinion in Nephrology and Hypertension*, vol. 24, no. 3, pp. 295–300, 2015.